Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service CGM & insulin pump management cases in Iowa: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (248 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 30 | 2,629 | 24% |
| 2020 | 33 | 3,099 | 27% |
| 2021 | 36 | 4,667 | 30% |
| 2022 | 37 | 5,765 | 34% |
| 2023 | 49 | 7,960 | 38% |
| 2024 | 54 | 9,706 | 40% |
| 2025 from claims | – | 10,806 9,917–11,433 | 41% |
| 2026 forecast | – | 12,022 10,578–13,873 | 40% |
| 2027 forecast | – | 13,126 11,222–15,643 | 40% |
| 2028 forecast | – | 14,331 11,958–17,548 | 41% |
| 2029 forecast | – | 15,646 12,779–19,621 | 41% |
| 2030 forecast | – | 17,080 13,684–21,888 | 42% |
CGM setup and interpretation codes identify who prescribes diabetes technology. Professional codes (what the surgeon bills): CPT 95249, 95250, 95251.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 50% of the cases CMS names in Iowa; 25 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 35% hospital outpatient, 65% office. The share outside the hospital has moved −19 pts since 2019.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 293 | 40,924+22%/yr | +22%/yr | 29.2 | 76% | 73,100 in 2030+10%/yr |
| Ohio | 278 | 30,536+34%/yr | +34%/yr | 27.1 | 66% | 55,500 in 2030+10%/yr |
| Indiana | 163 | 22,848+22%/yr | +22%/yr | 31.9 | 89% | 37,600 in 2030+8.6%/yr |
| Michigan | 215 | 22,586+13%/yr | +13%/yr | 26.2 | 68% | 36,200 in 2030+8.2%/yr |
| Missouri | 161 | 21,566+29%/yr | +29%/yr | 34.1 | 80% | 38,800 in 2030+10%/yr |
| Kansas | 76 | 13,034+33%/yr | +33%/yr | 31.9 | 84% | 23,200 in 2030+10%/yr |
| Wisconsin | 144 | 12,963+33%/yr | +33%/yr | 22.5 | 71% | 25,100 in 2030+12%/yr |
| Minnesota | 116 | 12,114+19%/yr | +19%/yr | 26.2 | 80% | 25,600 in 2030+13%/yr |
| Nebraska | 54 | 8,132+36%/yr | +36%/yr | 30.9 | 76% | 14,300 in 2030+9.9%/yr |
| South Dakota | 26 | 3,993+45%/yr | +45%/yr | 30.4 | 9% | 7,150 in 2030+10%/yr |
| North Dakota | 12 | 1,926+24%/yr | +24%/yr | 19.1 | 48% | 3,400 in 2030+9.9%/yr |
CGM & insulin pump management in every state, and its device makers · Every procedure market in Iowa · Every state · Compare with Illinois
Insulet leads with 32% of company spending on these surgeons in 2025, +24 pts on 2024.
In 2025, 9 companies reported engagement with Iowa’s surgeons worth $30K in consulting, speaking, meals and travel tied to these products, about $549 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 33 recalled product lines (8 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.